Quantisimo Corp., a sovereign quantum technology platform formed by WISeQey and SEALSQ, has signed a definitive business combination agreement with GigCapital8 Corp., a special purpose acquisition company (SPAC). This merger will create Quantisimo Holding Corp., a Nasdaq-listed company under the ticker "QSMO," expected to complete in Q1 2027. The transaction values Quantisimo at approximately $666 million and aims to integrate quantum computing, networking, and cybersecurity technologies with secure terrestrial and space infrastructure. WISeQey and SEALSQ will remain majority shareholders, supporting long-term development of the quantum platform.
Quantisimo Corp.'s business combination agreement with GigCapital8 Corp. is presented here with a snapshot of the Technology sector on Pluang as of Oct 09, 2026 11:01 WIB. Among 150 priced US tech stocks, 69 rose and 80 fell today. Mondaycom Ltd (MNDY) gained 6.45% to USD 88.90 with a typical hold time of 16 days, contrasting with Godaddy Inc (GDDY) at USD 103.46, which rose 6.43% but saw 99% sell orders and a much longer hold time of 65 days. Accenture plc (ACN) traded at USD 208.55, up 6.06%, with a typical hold time of 129 days and a more balanced order activity of 60% sell to 40% buy.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
